$ORRF

Orrstown Financial Services (ORRF) Stock Faces Forecast Doubts As Q2 Net Interest Margin Holds Near 4%

Simply Wall St reports Orrstown Financial Services (ORRF) posted Q2 2026 revenue of $62.3M, basic EPS of $1.10, and trailing twelve-month EPS of $4.48. Q2 net interest margin was 3.87% and cost-to-income 58.6%. Loans rose to $4.113B; nonperforming loans were $23.8M. Analysts expect revenue and earnings to decline over 3 years.

Original reporting
Published Jul 22, 2026, 11:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 23, 2026, 2:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Orrstown Financial Services (ORRF) Stock Faces Forecast Doubts As Q2 Net Interest Margin Holds Near 4% — source image
Decision brief

The 30-second read

$ORRFNeutralLow
01

Why it matters

Trader focus is on whether the reported NIM near 4% and loan growth can persist despite forecast contraction, which affects valuation multiples and dividend sustainability narratives.

02

Market read

The article is a valuation and forecast debate anchored to Q2 2026 NIM (3.87%) and credit metrics, but it does not introduce a new catalyst like guidance, a deal, or a regulatory action.

03

What to watch

The article does not quantify deposit beta, funding mix, or sensitivity to rate changes, which are key drivers of NIM sustainability for regional banks.

Relevance 4/10Novelty 4/10Timing: post-Q2 2026 results, focused on whether NIM near 4% can offset forecast declines

Background

The piece summarizes ORRF’s Q2 2026 performance and contrasts strong trailing profitability with consensus expectations for easing revenue, earnings, and net margins.

Company-level read

Ticker impact

$ORRFNeutralMedium confidence
Context

Orrstown Financial Services reported Q2 2026 net interest margin of 3.87% and discusses analyst expectations for revenue and margins to ease.

Expected impact

Likely limited near-term upside unless investors gain confidence that NIM and credit quality can hold versus the cited easing forecasts.

Evidence & confidence

This is primarily an analysis of reported Q2 metrics (NIM, cost-to-income, loans, non-performing loans) versus consensus growth assumptions, with no new guidance or event beyond the quarter’s figures.

Market effects

Small US banks’ valuation sensitivity to net interest margin durability is reinforced by the article’s focus on NIM holding near 4%.

No specific regional macro or bank peer read-across is provided beyond general lending and deposit conditions.

Minimal, as the piece is company-specific and does not introduce cross-border or global policy catalysts.

Counterpoint

Even if revenue and earnings forecasts are drifting down, ORRF’s stable NIM (3.87%) and contained non-performing loans could support a valuation re-rating if the market underestimates how long margins can stay elevated.

Key entities

  • Orrstown Financial Services

    US regional bank holding company; reported Q2 2026 revenue, EPS, net interest margin, loan growth, and non-performing loan level.

Related articles

$ORRFMed

Orrstown Financial Services, Inc. Reports Second Quarter 2026 Results

ORRSTOWN FINANCIAL SERVICES INC (ORRF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex9912026-q2earningsrelease.htm EX-99.1 Document Exhibit 99.1 FOR IMMEDIATE RELEASE: Orrstown Financial Services, Inc. Reports Second Quarter 2026 Results • Net income of $21.2 million, or $1.09 per diluted share, for the three months ended June 30, 2026 compared to net

$RAREHighAI 9/10

Ultragenyx agrees to sell voucher for US$210M

Ultragenyx Pharmaceutical (NASDAQ: RARE) agreed to sell a rare pediatric disease priority review voucher for $210M, nearly half its cash reserves. The deal, subject to regulatory approval, follows the FDA's August approval of its Genglycos gene therapy. Shares rose 2.97% on the news. Ultragenyx plans to use proceeds to advance rare disease therapies and support profitability. The price is within the range of recent voucher transactions, such as Rocket Pharmaceuticals' $180M deal.

$SLBMed

How New Energy Contracts Will Impact SLB (SLB) Stock

SLB (SLB) secured multi-year energy contracts with Aramco and ExxonMobil, expanding its backlog in onshore and deepwater infrastructure. Analysts project $43.0b revenue and $5.5b earnings by 2029, with potential upside. The company's focus on digital and data center solutions is seen as a driver for higher revenue.

$CEGMed

Big Tech Keeps Signing Nuclear Deals With the Same Company. Here's Who It Is and Why That Matters More Than Any Single Deal.

Constellation Energy (CEG) signed a deal with Alphabet's Google to supply 890 MW of nuclear power, highlighting its role in powering AI growth for tech giants. CEG operates outside regulated utilities, offering direct power sales to companies like Microsoft, Meta, and Amazon. Its scale, diverse energy portfolio, and long-term contracts support growth, though its stock remains 25% below 2025 highs.

$LCIDMed

Lucid Builds Fewer EVs Than It Sells As CEO’s Cash-Preservation Reset Takes Hold

Lucid Group reported Q3 production of 2,954 EVs and deliveries of 3,806, down from last year. The company is reducing inventory and aligning output with demand under CEO Silvio Napoli's operational reset. Lucid aims to improve cash flow by $1.4B in 2026. Analysts expect a Q3 loss of $2.30 per share and revenue of $570.42M. The stock has a Hold consensus rating with an average price target of $10.20.